(1)
Berwyn, Pennsylvania (Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ( Annovis or the Company ), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, is presenting new clinical efficacy and biomarker data of its drug ANVS401 during a one hour panel presentation, beginning at 8:00 p.m. ET today, July 28, at the 2021 Alzheimer s Association International Conference (AAIC) in Denver, Colorado.
The first part of the panel will feature Cheng Fang, PhD, Annovis Bio s VP of Research, an expert in axonal transport and protein aggregation. Dr. Fang will present the mechanism of action and will be followed by William Mobley, PhD, Distinguished Professor, Department of Neurosciences, and the Florence Riford Chair for Alzheimer s Research at the Un
Colorado
United-states
Berwyn
Pennsylvania
Denver
American
Marial-maccecchini
William-mobley
Priscilla-hernandez
Florence-riford
Cheng-fang
Annovis-bio